← Back to Search

Cognitive Bias Modification for Obsessive-Compulsive Disorder

Research Sponsored by Mclean Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adults (> 18 years old)
Primary diagnosis of OCD (as measured by a score of >16 on the Y-BOCS and a clinical diagnosis of OCD by their treatment team)
Screening 3 weeks
Treatment Varies
Follow Up time frame: weeks 0, 2, 4, and 8
Awards & highlights

Study Summary

This trial will test whether CBM-I is a feasible and acceptable augmentation to treatment as usual for OCD, and will examine preliminary efficacy by examining clinical outcomes associated with CBM-I.

Who is the study for?
This trial is for adults over 18 with a primary diagnosis of OCD, confirmed by specific clinical assessments. Participants must be able to complete computer tasks and consent to the main study protocol. Those with acute psychosis or a psychotic disorder cannot join.Check my eligibility
What is being tested?
The trial tests Cognitive Bias Modification for Interpretation (CBM-I), a digital intervention aimed at changing interpretation bias in OCD patients, against psychoeducation. It will assess CBM-I's feasibility, acceptability, and impact on OCD when added to usual treatment.See study design
What are the potential side effects?
Since CBM-I involves computer-based tasks and psychoeducation is informational, significant side effects are not anticipated. However, participants may experience discomfort or fatigue from focusing on a screen during sessions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am over 18 years old.
I have been diagnosed with OCD and my symptoms are moderate to severe.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time frame: weeks 0, 2, 4, and 8
This trial's timeline: 3 weeks for screening, Varies for treatment, and time frame: weeks 0, 2, 4, and 8 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Average Score on Yale-Brown Obsessive Compulsive Scale
Secondary outcome measures
Change in Average Score on Obsessive Beliefs Questionnaire

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Cognitive bias modification with treatment as usualExperimental Treatment1 Intervention
Participants in this group will receive usual treatment in the program up to 12 sessions of a digital cognitive training targeting interpretation bias
Group II: Psychoeducation with treatment as usualPlacebo Group1 Intervention
Participants in this group will receive usual treatment in the program up to 12 sessions of digitized psychoeducation

Find a Location

Who is running the clinical trial?

Mclean HospitalLead Sponsor
212 Previous Clinical Trials
21,488 Total Patients Enrolled
9 Trials studying Obsessive-Compulsive Disorder
637 Patients Enrolled for Obsessive-Compulsive Disorder

Media Library

Psychoeducation Clinical Trial Eligibility Overview. Trial Name: NCT05224414 — N/A
Obsessive-Compulsive Disorder Research Study Groups: Cognitive bias modification with treatment as usual, Psychoeducation with treatment as usual
Obsessive-Compulsive Disorder Clinical Trial 2023: Psychoeducation Highlights & Side Effects. Trial Name: NCT05224414 — N/A
Psychoeducation 2023 Treatment Timeline for Medical Study. Trial Name: NCT05224414 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there currently any open enrollments for this clinical experiment?

"According to the clinicaltrials.gov website, this study is looking for participants and has been actively recruiting since its initial posting on March 24th 2022. The details of the trial were most recently updated April 7th 2022."

Answered by AI

What is the capacity of this research endeavor?

"Affirmative. Information available on clinicaltrials.gov shows that recruitment for this trial is currently in progress and commenced on March 24th 2022. As of April 7th, the medical study has been looking to enrol 106 volunteers from one location."

Answered by AI
~56 spots leftby Aug 2026